Soluble suppression of tumorigenicity 2 (sST2) in chronic heart failure


DOI: https://dx.doi.org/10.18565/therapy.2022.4suppl.68-70

Kravchenko A.Ya., Chernik T.A., Tokmachev R.E.

Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russian Federation
Abstract. The aim of the study was to determine the relationship of soluble suppression of tumorigenicity 2 (sST2) with the diagnostic characteristics of patients with chronic heart failure. The data obtained may indicate a pathogenetic relationship between sST2 and systolic and diastolic dysfunction of the left ventricle, as well as dysfunction of the right heart.
Keywords: suppression of tumorigenicity 2 (sST2), chronic heart failure, biomarkers
Read entire article

Literature

1. Bozkurt B., Coats A.J.S., Tsutsui H. et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021; 23(3): 352–80. doi: 10.1002/ejhf.2115.


2. Кожевникова М.В., Беленков Ю.Н. Биомаркеры сердечной недостаточности: настоящее и будущее. Кардиология. 2021; 5: 4–16. doi: 10.18087/cardio.2021.5.n1530.


3. Vianello E., Dozio E., Tacchini L. et al. ST2/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019; 116: 105619. doi: 10.1016/j.biocel.2019.105619.


Similar Articles

Back to Content

Бионика Медиа